BellBrook Labs

BellBrook Labs is a biotechnology startup based in the United States, founded in 2007. The company is committed to speeding up drug discovery and biological research to enable the pharmaceutical industry to develop more effective therapies. Their proprietary Transcreener® HTS Platform is designed to expedite the movement of new targets into high-throughput screening (HTS) and simplify selectivity profiling within a target family. This technology, based on homogenous fluorescent immunodetection of nucleotides, has been rapidly validated and adopted by pharmaceutical and biotechnology screening labs globally. In June 2012, BellBrook Labs received a $187.29K investment in a Seed Round. The company's commitment to addressing critical technical challenges in drug discovery and their innovative technological solutions make them an attractive investment opportunity for venture capitalists looking to support advancements in the pharmaceutical industry.